Express Scripts and FTC Announce Settlement

February 12, 2026

EGWP marketplace medicaid Medicare

On Feb. 4, Express Scripts and the Federal Trade Commission (FTC) announced a comprehensive resolution settlement that addresses concerns raised by the FTC. Details of the global settlement include:

  • As enforced by the settlement, our new, transparent pharmacy benefits model ensures that our patients pay the lowest available cost for their medicines, whether it is our negotiated cost, their copay, or a cash discount price.
  • TrumpRx pricing will be covered for our members so that purchases through TrumpRx will count towards their deductible upon relevant legal and regulatory changes.
    • Express Scripts is the first PBM to partner with TrumpRx, and this would be the first time TrumpRx pricing is available to patients as part of their pharmacy benefits.
  • Ensure Express Scripts’ new industry-leading and transformative price discount (rebate-free) model is widely available to employers and health plan sponsors to lower the cost of all brand medications for their members as our new standard model.
  • Ensure our new reimbursement model based off the pharmacy’s actual acquisition costs is available to retail community pharmacies, and that retail community pharmacies are compensated for other essential clinical services (e.g., certain diagnostic testing and vaccinations).
  • Ensure more lower-priced medicines, including insulins, are covered across all Express Scripts standard formularies – and that our Patient Assurance Program that caps the monthly cost of insulin at $25 is the standard for Express Scripts’ clients.
  • Support the American economy by moving rebate contracting operations conducted on Express Scripts’ behalf to the U.S. 

These are meaningful steps toward making prescription drugs more affordable for millions of families and advancing the goals we share with the administration of full transparency into prescriptions drug costs. This settlement enables us to keep moving forward, and we appreciate the Administration’s reinforcement of our commitment to pharmacy benefits that put Americans first.

survey results

Take the 1-Minute survey

Thank you for being a valued reader of Regulated Times. Take our brief, anonymous survey in less than one minute and help shape the future of Regulated Times.

As we continue to evolve the newsletter, we’d love to hear your thoughts. Your feedback will help us better understand what content is most valuable, whether the current publication frequency is meeting your needs, and how we can improve your overall experience.
read more >

June 19, 2026

EGWP marketplace medicaid Medicare

legislation

Bicameral Patients before Monopolies Act reintroduced

On May 13, bipartisan lawmakers in the House and Senate reintroduced the Patients Before Monopolies (PBM) Act (S.4509/H.R.8779), legislation that would prohibit common ownership of PBMs, insurers, and pharmacies. Sponsored by Sens. Warren (D-MA) and Josh Hawley (R-MO) alongside Reps. Diana Harshbarger (R-TN) and Jake Auchincloss (D-MA), the bill would require impacted organizations to divest […]
read more >

June 10, 2026

EGWP marketplace medicaid Medicare

legislation

CMS announces ePA acceleration initiative, democrats seek to repeal WISeR Model

The Centers for Medicare & Medicaid Services (CMS) is advancing its electronic prior authorization (ePA) efforts through a newly established Electronic Prior Authorization Acceleration initiative to address key challenges and drive solutions ahead of 2027 requirements. To date, 29 health care organizations – including health systems, electronic health record developers, physician practices, networks, and digital health […]
read more >

June 10, 2026

EGWP marketplace medicaid Medicare

You may also like